We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT (DEXTERITY-SCI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04858776
Recruitment Status : Recruiting
First Posted : April 26, 2021
Last Update Posted : January 26, 2023
Sponsor:
Collaborators:
Sentara Norfolk General Hospital
Medstar Health Research Institute
Vascular Care Connecticut
University of South Florida
Guy's and St Thomas' NHS Foundation Trust
University College Hospital Galway
OhioHealth Research Institute
CIS Clinical Research
NC Heart and Vascular Research, LLC
Lake Washington Vascular
Memorial Hermann Hospital
St. John Health System, Oklahoma
CardioVoyage, LLC
Stony Brook University
Charlotte-Mecklenburg Hospital
Northwestern University
King County Public Hospital
Information provided by (Responsible Party):
Mercator MedSystems, Inc.

Tracking Information
First Submitted Date  ICMJE April 21, 2021
First Posted Date  ICMJE April 26, 2021
Last Update Posted Date January 26, 2023
Actual Study Start Date  ICMJE August 8, 2022
Estimated Primary Completion Date May 31, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 21, 2021)
  • Clinically relevant primary patency [ Time Frame: 6 months ]
    Freedom from loss of patency with associated symptoms
  • Freedom from major adverse event (MAE) [ Time Frame: 30 days ]
    Freedom from composite of all-cause death, clinically significant pulmonary embolism, major bleeding, target vessel thrombosis, infection of treatment or insertion site, or AV fistula of treatment site
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
Official Title  ICMJE Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT (DEXTERITY-SCI)
Brief Summary This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for at least 14 days and no more than 60 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up to 24 months after the initial DVT recanalization procedure.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Iliofemoral; Thrombosis
Intervention  ICMJE
  • Combination Product: Perivascular dexamethasone
    Dexamethasone delivery around target vein segment(s)
  • Combination Product: Perivascular sham
    Saline delivery around target vein segment(s)
Study Arms  ICMJE
  • Experimental: Treatment
    Intervention: Combination Product: Perivascular dexamethasone
  • Sham Comparator: Control
    Intervention: Combination Product: Perivascular sham
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 21, 2021)
60
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 31, 2024
Estimated Primary Completion Date May 31, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Provision of signed and dated informed consent form prior to receiving any non-standard of care, protocol-specific procedures.
  2. Stated willingness to comply with all study procedures including completion of questionnaires and follow-up visits and availability for the duration of the study.
  3. Male or female, aged 18 to 89 years.
  4. For females of reproductive potential: negative pregnancy test ≤7 days before the procedure, use of highly effective contraception for at least 1 month prior to screening, and agreement to use such a method during study participation.
  5. Negative COVID-19 test result within 5 days prior to procedure or evidence of COVID-19 vaccine or booster within past 12 months.
  6. Onset of DVT symptoms 14 to 60 days prior to intervention in the study limb with need for stenting of the iliofemoral segment.
  7. Ability to take oral medication and be willing to adhere to the prescribed anti-coagulant regimen.
  8. Prescription for at least 14 days low molecular weight heparin followed by therapeutic anticoagulant of investigator's choice for 12-month minimum as part of post-interventional medication regimen.
  9. Minimum of 30 days of prescribed antiplatelet agent (aspirin or P2Y12 inhibitor).
  10. Hemodynamically significant DVT (>50% area obstruction) spanning at least (a) the iliofemoral and common femoral veins or (b) the common femoral vein with extension into the femoral vein and/or profunda vein. Extent of thrombus in the popliteal and calf veins is allowed.
  11. Successful recanalization of the target vein with at least one patent inflow vein (femoral or profunda).

Exclusion Criteria:

  1. Current enrollment in another non-registry clinical study of systemic drug therapy or another device study that has not completed its primary endpoint, including prior enrollment in this study. Concurrent enrollment in registry studies of approved devices or drugs are acceptable.
  2. Lack of capability of understanding the nature, significance and implications of the clinical trial.
  3. Body Mass Index > 40 kg/m2.
  4. Non-ambulatory status prior to DVT occurrence.
  5. In the target vein segment: previously treated symptomatic DVT within the previous 12 months.
  6. In the contralateral (non-study) leg: symptomatic DVT that, in the opinion of the operating physician, will require surgery in the following 30 days.
  7. Limb-threatening circulatory compromise with ankle-brachial index <0.4, absolute ankle pressure <50 mmHg or absolute toe pressure <30 mmHg.
  8. Pulmonary embolism (PE) defined as either massive (Systolic blood pressure < 90 mmHg and/or patient on IV vasoactive medication to support blood pressure), or intermediate high-risk PE, as defined by the European Society Guideline on management of PE. Low-risk PE and/or intermediate low-risk PE can be enrolled.
  9. Inability to tolerate contemporary venous intervention procedure due to severe dyspnea or acute systemic illness.
  10. Allergy, hypersensitivity, or thrombocytopenia from heparin, Recombinant tissue plasminogen activator (rtPA), dexamethasone sodium phosphate or iodinated contrast, except for mild-moderate contrast allergies for which steroid pre-medication can be used.
  11. History of, or active heparin-induced thrombocytopenia (HIT).
  12. Haemoglobin < 9.0 mg/dl, INR > 1.6 before starting anticoagulation, or platelets < 100,000/ml. Moderate renal impairment in diabetic patients (estimated glomerular filtration rate < 60 ml/min) or severe renal impairment in non-diabetic patients (estimated glomerular filtration rate < 30 ml/min).
  13. Active bleeding, recent (< 3 mo) GI bleeding, severe liver dysfunction, bleeding diathesis.
  14. Recent (< 3 mo) internal eye surgery or haemorrhagic retinopathy; recent (< 10 days) major surgery, cataract surgery, trauma, cardiopulmonary resuscitation, obstetrical delivery, or other invasive procedure.
  15. History of hemorrhagic stroke or intracranial/intraspinal bleed, tumor, vascular malformation, aneurysm.
  16. Active cancer with a life expectancy of <2 years.
  17. Severe hypertension on repeated readings (systolic blood pressure > 180 mmHg or diastolic blood pressure > 105 mmHg). This can be treated, and blood pressure must be stable before venous access is obtained (systolic blood pressure <140 mmHg).
  18. Pregnant or breastfeeding.
  19. Life expectancy < 2 years.
  20. Thrombus of the inferior vena cava (IVC) extending at least one centimeter above the common iliac confluence.
  21. Inability to obtain venous access.
  22. Inability to recanalize the target vein segment(s).
  23. History of ipsilateral venous stent.
  24. DVT length to be targeted for perivascular drug therapy exceeds 50 cm.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 89 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Kirk Seward, PhD 510-614-4550 kseward@mercatormed.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04858776
Other Study ID Numbers  ICMJE CIP0218
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Mercator MedSystems, Inc.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Mercator MedSystems, Inc.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE
  • Sentara Norfolk General Hospital
  • Medstar Health Research Institute
  • Vascular Care Connecticut
  • University of South Florida
  • Guy's and St Thomas' NHS Foundation Trust
  • University College Hospital Galway
  • OhioHealth Research Institute
  • CIS Clinical Research
  • NC Heart and Vascular Research, LLC
  • Lake Washington Vascular
  • Memorial Hermann Hospital
  • St. John Health System, Oklahoma
  • CardioVoyage, LLC
  • Stony Brook University
  • Charlotte-Mecklenburg Hospital
  • Northwestern University
  • King County Public Hospital
Investigators  ICMJE Not Provided
PRS Account Mercator MedSystems, Inc.
Verification Date January 2023

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP